KR20220097921A - 인터루킨-22의 치료 유도체 - Google Patents

인터루킨-22의 치료 유도체 Download PDF

Info

Publication number
KR20220097921A
KR20220097921A KR1020227017744A KR20227017744A KR20220097921A KR 20220097921 A KR20220097921 A KR 20220097921A KR 1020227017744 A KR1020227017744 A KR 1020227017744A KR 20227017744 A KR20227017744 A KR 20227017744A KR 20220097921 A KR20220097921 A KR 20220097921A
Authority
KR
South Korea
Prior art keywords
derivative
hil
leu
disease
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227017744A
Other languages
English (en)
Korean (ko)
Inventor
크리스티안 사스-외룸
라스무스 예르겐센
세바스티안 베크 예르겐센
헨닝 퇴게르센
토마스 호에그-옌센
미카엘 파올로 바스트네르 산드리니
Original Assignee
쉬토키 파르마 에이피에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쉬토키 파르마 에이피에스 filed Critical 쉬토키 파르마 에이피에스
Publication of KR20220097921A publication Critical patent/KR20220097921A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
KR1020227017744A 2019-11-07 2020-11-09 인터루킨-22의 치료 유도체 Ceased KR20220097921A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19207766.7A EP3819307A1 (en) 2019-11-07 2019-11-07 Therapeutic derivatives of interleukin-22
EP19207766.7 2019-11-07
PCT/EP2020/081523 WO2021089875A1 (en) 2019-11-07 2020-11-09 Therapeutic derivatives of interleukin-22

Publications (1)

Publication Number Publication Date
KR20220097921A true KR20220097921A (ko) 2022-07-08

Family

ID=68502950

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227017744A Ceased KR20220097921A (ko) 2019-11-07 2020-11-09 인터루킨-22의 치료 유도체

Country Status (19)

Country Link
US (5) US11806403B2 (https=)
EP (2) EP3819307A1 (https=)
JP (2) JP2023502005A (https=)
KR (1) KR20220097921A (https=)
CN (2) CN118359699A (https=)
AU (1) AU2020378648A1 (https=)
BR (1) BR112022008497A2 (https=)
CA (1) CA3160338A1 (https=)
CL (1) CL2022001185A1 (https=)
CO (1) CO2022005889A2 (https=)
CR (1) CR20220249A (https=)
GE (2) GEP20257757B (https=)
IL (1) IL292657A (https=)
MX (1) MX2022005547A (https=)
MY (1) MY209488A (https=)
PE (1) PE20221279A1 (https=)
PH (1) PH12022551107A1 (https=)
SA (1) SA522432487B1 (https=)
WO (1) WO2021089875A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3819307A1 (en) 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
WO2021207662A1 (en) * 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
BR112022020796A2 (pt) * 2020-04-17 2022-11-29 Univ Leland Stanford Junior Polipeptídeos de interleucina-22 projetados e usos do mesmos
WO2024133936A2 (en) 2022-12-22 2024-06-27 Cytoki Pharma Aps Dosage regimen for interleukin-22 derivatives
EP4389138A1 (en) 2022-12-22 2024-06-26 Cytoki Pharma ApS Dosage regimen for interleukin-22 derivatives
CN119708194A (zh) * 2023-09-28 2025-03-28 南京诺艾新生物技术有限公司 Il-22突变体及其制备方法与应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR106F (https=) 1964-12-21
CA2718634A1 (en) 2008-03-21 2009-09-24 Wyeth Llc Antibodies against interleukin-10-like cytokines and uses therefor
WO2011154349A2 (en) 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
TW201143790A (en) * 2010-05-13 2011-12-16 Univ Indiana Res & Tech Corp Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
BR112013015898A2 (pt) * 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素（ｒｅｌａｘｉｎ）融合多肽類及其用途
CA2878825A1 (en) 2012-07-10 2014-01-16 The Uab Research Foundation Compositions and methods for modulation of il-20 family cytokine activity
WO2014145016A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
JP6822839B2 (ja) * 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
US10695406B2 (en) 2014-05-27 2020-06-30 The University Of Queensland Modulation of cellular stress using a B-cell oxidative and/or endoplasmic reticulum stress inhibitor and a targeting agent
MA41794A (fr) 2015-03-18 2018-01-23 The California Institute For Biomedical Res Agents thérapeutiques modifiés et compositions associées
CN106146668A (zh) 2015-04-01 2016-11-23 中国人民解放军第二军医大学 长效白细胞介素22的制备方法及其用途
MX384213B (es) * 2015-07-15 2025-03-14 Protagonist Therapeutics Inc Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias.
KR20240141853A (ko) * 2017-08-03 2024-09-27 신톡스, 인크. 자가면역 질환의 치료를 위한 사이토카인 접합체
CR20200327A (es) 2018-01-26 2020-11-05 Genentech Inc Proteínas de fusión fc il-22 y métodos de uso
EP3819307A1 (en) * 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
BR112022020796A2 (pt) 2020-04-17 2022-11-29 Univ Leland Stanford Junior Polipeptídeos de interleucina-22 projetados e usos do mesmos
EP4089107A1 (en) 2021-05-11 2022-11-16 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
WO2022238510A1 (en) 2021-05-11 2022-11-17 Cytoki Pharma Aps Therapeutic derivatives of interleukin-22
EP4089108A1 (en) 2021-05-11 2022-11-16 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22

Also Published As

Publication number Publication date
SA522432487B1 (ar) 2024-10-01
PH12022551107A1 (en) 2023-11-20
CN114761422B (zh) 2026-01-02
AU2020378648A1 (en) 2022-06-23
JP7479539B2 (ja) 2024-05-08
US11806403B2 (en) 2023-11-07
WO2021089875A1 (en) 2021-05-14
CO2022005889A2 (es) 2022-07-29
BR112022008497A2 (pt) 2022-07-26
US12447211B2 (en) 2025-10-21
PE20221279A1 (es) 2022-09-05
EP3819307A1 (en) 2021-05-12
GEAP202415970A (en) 2024-12-25
CR20220249A (es) 2022-08-19
US20230381320A1 (en) 2023-11-30
JP2023502005A (ja) 2023-01-20
US20240252649A1 (en) 2024-08-01
CA3160338A1 (en) 2021-05-14
MX2022005547A (es) 2022-07-04
GEP20257757B (en) 2025-04-10
EP4055035A1 (en) 2022-09-14
CN118359699A (zh) 2024-07-19
US20220347304A1 (en) 2022-11-03
US20240108731A1 (en) 2024-04-04
MY209488A (en) 2025-07-12
JP2023083380A (ja) 2023-06-15
CL2022001185A1 (es) 2023-02-03
IL292657A (en) 2022-07-01
US20260014257A1 (en) 2026-01-15
US12226487B2 (en) 2025-02-18
CN114761422A (zh) 2022-07-15

Similar Documents

Publication Publication Date Title
KR20220097921A (ko) 인터루킨-22의 치료 유도체
TWI670281B (zh) Ｇｉｐ－ｇｌｐ－１雙重促效劑化合物及方法
KR100733940B1 (ko) 폴리에틸렌 글리콜이 연결된 ｇｌｐ-1 화합물
US20190270789A1 (en) Glucagon-glp-1-gip triple agonist compounds
JP2012067100A (ja) Ｉｌ−２１の誘導体
US20240279297A1 (en) Therapeutic derivatives of interleukin-22
CN117597357A (zh) 白细胞介素-22的治疗性衍生物
CN117616035A (zh) 白介素-22的治疗性衍生物
JP2007533298A (ja) Ｉｌ−２１の誘導体
JP4237703B2 (ja) インスリン様成長因子結合タンパク質−４及びポリ（エチレングリコール）の接合体
WO2006122162A2 (en) Use of peptides derived from the growth factor amp-18 for the treatment of mucositis
HK40108760A (zh) 白细胞介素-22的治疗性衍生物
EA049770B1 (ru) Терапевтические производные интерлейкина-22
US20080194479A1 (en) Methods and Compositions to Treat Mucositis
EP1885390B1 (en) Use of peptides derived from the growth factor amp-18 for the treatment of oral mucositis
CA2643736A1 (en) Methods and compositions to treat mucositis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601